Diabetes Metab J.  2018 Aug;42(4):343-347. 10.4093/dmj.2017.0082.

Serum Soluble Epidermal Growth Factor Receptor Level Increase in Patients Newly Diagnosed with Type 2 Diabetes Mellitus

• Kim JM
• Choung S
• Joung KH
• Lee JH
• Kim HJ
• Ku BJ

• KMID: 2418723
• DOI: http://doi.org/10.4093/dmj.2017.0082

Abstract

We analyzed circulating soluble epidermal growth factor receptor (sEGFR) levels in humans. Serum sEGFR levels were higher in subjects with newly diagnosed type 2 diabetes mellitus compared with controls. Serum sEGFR was positively correlated with glycosylated hemoglobin and serum glucose and negatively correlated with serum insulin and C-peptide levels.

Keyword

Biological assay; Diabetes mellitus, type 2; Receptor, epidermal growth factor

MeSH Terms

Biological Assay
Blood Glucose
C-Peptide
Diabetes Mellitus, Type 2*
Epidermal Growth Factor*
Hemoglobin A, Glycosylated
Humans
Insulin
Receptor, Epidermal Growth Factor*
C-Peptide
Epidermal Growth Factor
Insulin
Receptor, Epidermal Growth Factor

Reference

1. Guillaudeau A, Durand K, Bessette B, Chaunavel A, Pommepuy I, Projetti F, Robert S, Caire F, Rabinovitch-Chable H, Labrousse F. EGFR soluble isoforms and their transcripts are expressed in meningiomas. PLoS One. 2012; 7:e37204. PMID: 22623992.

2. Wilken JA, Perez-Torres M, Nieves-Alicea R, Cora EM, Christensen TA, Baron AT, Maihle NJ. Shedding of soluble epidermal growth factor receptor (sEGFR) is mediated by a metalloprotease/fibronectin/integrin axis and inhibited by cetuximab. Biochemistry. 2013; 52:4531–4540. PMID: 23731208.

3. American Diabetes Association. 2. Classification and diagnosis of diabetes. Diabetes Care. 2016; 39(Suppl 1):S13–S22. PMID: 26696675.

4. Jantus-Lewintre E, Sirera R, Cabrera A, Blasco A, Caballero C, Iranzo V, Rosell R, Camps C. Analysis of the prognostic value of soluble epidermal growth factor receptor plasma concentration in advanced non-small-cell lung cancer patients. Clin Lung Cancer. 2011; 12:320–327. PMID: 21729651.

5. Racil Z, Razga F, Drapalova J, Buresova L, Zackova D, Palackova M, Semerad L, Malaskova L, Haluzik M, Mayer J. Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia. Haematologica. 2013; 98:e124–e126. PMID: 23716549.

6. Villadolid J, Ersek JL, Fong MK, Sirianno L, Story ES. Management of hyperglycemia from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) targeting T790M-mediated resistance. Transl Lung Cancer Res. 2015; 4:576–583. PMID: 26629426.

7. Huda MS, Amiel SA, Ross P, Aylwin SJ. Tyrosine kinase inhibitor sunitinib allows insulin independence in long-standing type 1 diabetes. Diabetes Care. 2014; 37:e87–e88. PMID: 24757248.

8. Kyohara M, Shirakawa J, Okuyama T, Kimura A, Togashi Y, Tajima K, Hirano H, Terauchi Y. Serum quantitative proteomic analysis reveals soluble EGFR to be a marker of insulin resistance in male mice and humans. Endocrinology. 2017; 158:4152–4164. PMID: 29028997.

9. Miettinen PJ, Ustinov J, Ormio P, Gao R, Palgi J, Hakonen E, Juntti-Berggren L, Berggren PO, Otonkoski T. Downregulation of EGF receptor signaling in pancreatic islets causes diabetes due to impaired postnatal beta-cell growth. Diabetes. 2006; 55:3299–3308. PMID: 17130473.

10. Miettinen P, Ormio P, Hakonen E, Banerjee M, Otonkoski T. EGF receptor in pancreatic beta-cell mass regulation. Biochem Soc Trans. 2008; 36(Pt 3):280–285. PMID: 18481942.